Investor Moves
| Name | Value | Action | Change | Price | Last Price |
|---|---|---|---|---|---|
Steven CohenPoint72 $-434.9K ExitQ4 2025 $435k $23.78 $4.62 | |||||
Insider Trades
| Name | Value | Action | Price | Last Price |
|---|---|---|---|---|
Grant Grady IIIDirector $20k13.5k shares BuyNov 10, 2025 $1.49 $4.62 | ||||
News
accessnewswire.comAptevo Therapeutics Appoints Mary J. Janatpour, Ph.D.accessnewswire.comMay 28
accessnewswire.comAptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closingaccessnewswire.comMay 27
zacks.comAll You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buyzacks.comMay 20
accessnewswire.comAptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selectionaccessnewswire.comMay 13
accessnewswire.comAptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selectionaccessnewswire.comMay 6